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Abstract
Alzheimer’s disease (AD) is a chronic neurodegenerative disease and is the sixth leading cause of
death in the United States with approximately 5.5 million Americans diagnosed with it. The
neuropathological hallmark includes extracellular senile plaques and intraneuronal neurofibrillary
tangles. Recent GWAS studies have identified genes associated with AD, and have revealed
several classes of genes implicated in disease pathogenesis. In particular, three general pathways
associated with an increased risk of AD included: 1) cholesterol metabolism, innate immune
system, and the membrane trafficking. Our lab has focused on intracellular trafficking as it relates
to the processing of amyloid precursor protein (APP), the precursor protein for the Aβ peptide—a
critical component of the senile plaque. Much is still unknown about the intracellular itinerary of
APP, and the cellular location of Aβ production. Here, I describe the use of click-chemistry applied
to an APP construct to further study APP processing. In addition, I describe work that I did to
develop a microfluidic system to enable visualizing APP processing within the unique
cytoarchitecture of primary neurons. Microfluidics helps in isolating the soma and axon to
understand APP processing in these specific compartments.
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CHAPTER 1
Introduction
Alzheimer’s disease is a chronic neurodegenerative disease and is the sixth leading cause of death
in the United States with approximately 5.5 million Americans diagnosed with it 1. The major
pathological hallmark for Alzheimer’s is accumulation of insoluble deposits of amyloid-beta (Aβ)
peptide. GWAS studies for AD showed various factors of which the genes in the intracellular
pathway of APP has gained the most attention2 . This peptide is obtained by the sequential
proteolytic cleavage of amyloid precursor protein (APP) 3. One of the challenges in understanding
this disease has been in elucidating the trafficking and processing of Aβ. To understand this
problem Aβ has been engineering by click-labelling 4 to visualize the trafficking.

1.1 Proteolytic processing of APP
The amyloid-beta (Aβ) peptide is made up of 37-43 amino acids, obtained by proteolytic
cleavage of amyloid precursor protein (APP). APP is a type-I oriented membrane protein
with its carboxyl (C) terminal in the cytosol and the amino (N) terminal in the lumen. APP
is proteolytically processed at several different subcellular locations and is targeted by
three different proteases – alpha (α), beta (β) and gamma (γ) secretases 3.
APP can undergo two processes- the amyloidogenic pathway that leads to the generation
of Aβ and the anti-amyloidogenic pathway that prevents the generation of Aβ (figure 1.1)3.
The amyloidogenic pathway produces Aβ by the consecutive action of β and γ secretase.
The β-secretase activity initiates Aβ generation by shedding the ectodomain of APP
1

(APPsβ) and generates the C-terminal (βCTF) that is cleaved by the γ -secretase. Following
the γ-secretase cleavage, Aβ is found in the extracellular fluids like plasma and
cerebrospinal fluid 3.
In the anti-amyloidogenic pathway, APP is cleaved nearly in the middle of the Aβ region
by α-secretase giving rise to α-CTF, followed by γ-secretase cleavage resulting in the
generation of a small 3kDa peptide called p3. Apart from p3 and Aβ, γ-secretase also
generates APP intracellular domain (AICD) that is involved in nuclear signaling 3.

Figure-1.1: Anti-amyloidogenic and amyloidogenic processing of APP

1.2 Cellular trafficking of APP
In non-polarized mammalian cell lines, APP transits from endoplasmic reticulum (ER) to
the plasma member (PM). During this transit, APP is post-translationally modified. in the
Golgi apparatus and the trans-Golgi network (TGN). Membrane APP that hasn’t been shed
(due to alpha-secretase cleavage) is internalized due to the presence of the “YENPTY”
motif near the C-terminus. Following this, APP is sent to endosomes and a fraction of the

2

endocytosed molecules is recycled to the cell surface, recycled to the TGN, or trafficked
down the lysosomal pathway 3.

Figure-1.2.a: Cellular trafficking of APP in non-polarized cells.

In neurons, the trafficking is complicated due to the various compartments in the neuronssoma, axon and dendrites. APP trafficking in the neuronal soma is similar to that of the
non-neuronal cell, that is, it transports from ER to Golgi and TGN. After leaving the TGN,
APP is transported to axons and dendrites in post Golgi transport vesicles. APP delivery to
axons makes use of fast axonal transport system but there are several theories with respect
to its processing 3.

3

Figure-1.2.b:APP and secretases transport in neurons.

1.3 APP processing in axons
APP processing in neurons is still not understood due to the complex system of
compartmentalizing and transport. Two models had been proposed as to the processing of
APP in axons. One model postulated by Muresan et.al. 2009, states that APP is processed
in the soma and the cleaved products gets sorted into axons. This is supported by finding
that the endocytic sorting pathway for the β secretase: BACE-1, is limited largely to the
soma. But a recent paper by Thinakaran et.al.2015 found BACE-1 enriched in axons5.
Another model proposes local processing in axons/synapses with extracellular APP
fragments. This model is supported by the evidence that there is colocalization of
processing enzymes together with APP in vesicles and evidence that synaptic activity in
vivo increases due to endocytosis-dependent Aβ release in the brain. From these finding it
can be deduced that Aβ secretion is dependent on synaptic activity and endocytosis,
implicating synapses as the site of processing and secretion 6.

4

A recent paper by Niederst et.al 2015, used compartmentalized culture system to study the
processing. A microfluidic system was used to study Aβ generation. The samples from the
axonal compartment was collected and Aβ measured. The Aβ fragments were identified
using immunoassay. The amount of protein secreted per axon was calculated as by
multiplying the volumes from both soma and axons with APP fragment concentration and
divided by number of axons per chamber. To estimate the number of molecules secreted
per axon, Avogadro’s number was multiplied with the fragment concentration. Total
axonal concentration was calculated by subtracting the APP amount from the somal
chamber. They compared mouse and human hippocampal neurons and found the result to
be consistent. They determined that about 70-80% of APP is being processed in the soma6.
One of the concerns is to understand whether APP fragments are endocytosis- independent
or dependent. They found that axonal Aβ generation is dependent on endocytosis sorting
and is a major pathway. This was found by using dynasore, a dynamin inhibitor, reduced
the amount of axonal APP suggesting that it is endocytic dependent. 6.
So far, the sorting of APP fragments was understood but not for full length-APP (FL-APP).
They found that FL-APP can enter the axon in endocytosis independent pathway 6.

5
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b

Figure 1.3.a: a) Comparison of APP and it’s fragments in soma versus axon
b) Graph indicating endocytosis as major pathway for axonal Aβ generation
c) Graph indicating that FL-APP sorting is endocytosis independent

They also found that there are multiple pathways for axonal sorting of APP, Aβ and
BACE1 sorting 6.

Figure 1.3.b: Colocalization of APP, Aβ and BACE1 with subcellular markers

One of the key questions that remains unanswered is the site of Aβ generation and it’s
trafficking in the neurons. To understand, Das et.al 2013, designed an assay called
OptiCAB to find the sites of interaction of APP and BACE1 to better understand the first
6

cleavage event leading to Aβ generation. As with the previous study, they found soma to
be region of maximum interaction of APP and BACE-1. They found that APP and BACE1 was co-transported in axons and can interact during transit. Immobile APP and BACE-1
particles were found near the dendrites and presynaptic boutons 7.
The result from this paper indicate that APP and BACE-1 interact in both endocytosis and
biosynthetic compartments, in recycling endosomes distributed throughout the neuronal
processes and in Golgi-derived vesicles in which they are co-transported. It also implicates
recycling microdomains (dendritic spines and presynapses) as important sites of APP and
BACE-1 convergence. Also show that APP endocytosed from the plasma membrane enters
late endosomes or lysosomes 7.

Figure 1.3.c: Colocalization of APP-BACE1 in dendrites with recycling endosomes (TfR &
Rab11), early endosomes (Rab5), lysosome (LAMP1), Golgi (NPYss)

7

Figure 1.3.d: Colocalization of APP-BACE1 in axons and presynaptic boutons with recycling
endosomes (TfR & Rab11), early endosomes (Rab5), lysosome (LAMP1), Golgi (NPYss)

These studies show an indirect relation to the possible subcellular location of Aβ and it’s
trafficking is still unknown. To address this issue, APP was click-labelled in the Aβ region
to help in identifying it’s trafficking. This works consists of validation of the clickedlabelled Aβ and fabrication of microfluidic devices to help in neuronal studies.

1.4 Microfluidics
Microfluidics is the science and technology of systems that process and manipulate small
amounts of fluids in a geometrically constrained scale. It provides several advantages in
analysis as it exploits both it’s small scale and the characteristics of fluids in the microchannels. Some of these advantages include decreased cost of manufacture, use ad disposal,
decreased time of analysis, reduced consumption of reagent and analytes, reduced
production of potentially harmful byproducts, increased separation efficiency and
portability and decreased weight and volume 8. It has uses in molecular analysis,

8

biodefense, molecular biology, microelectronics, clinical diagnostics and drug
development 9.
Fluid dynamics inside the microfluidics gives a unique advantage to them. The Reynold’s
number in micro-channels is less than 2000 and flow is laminar. In these conditions gravity
is less important, and the surface forces become dominant to influence the flow. The
mixing of fluids in this system is only by diffusion. Electro-osmotic flow can be observed
for charged fluids 10.

Figure 1.4.a: Laminar flow seen in micro-channels
Most microfluidic systems are carried out in polymers like poly(dimethylsiloaxane) or
PDMS. The properties of PDMS has various advantages that makes it favorable for
microfluidics. Some of these properties include its elastomeric nature, it’s optical
transparent and can absorb wavelength in 240-1100 nm range, it acts as an insulator, it’s
non-toxic and biocompatible. It is permeable to gases and compatible with water and polar
solvents 10.
The surface chemistry of PDMS can be changed easily to exploit it for our uses. PDMS is
hydrophobic, that consists of repeating units of –O-Si(CH3)2. When it is exposed to oxygen,
air, plasma or UV, there is loss of the methyl group to make PDMS hydrophilic. The
hydrophilic nature is reversible and to prevent it from reverting back, PDMS should be
9

kept in contact with polar solvents. Due to it’s hydrophobicity, PDMS can be reversibly
bond onto glass or irreversible bond after plasma/UV treatment 10.
Microfluidic system made of PDMS are fabricated using soft lithography technique. This
includes using rapid prototyping for device design using AutoCAD, followed by replica
molding of PDMS 11.

Figure 1.4.b: Fabrication process of microfluidic devices made from PDMS

Due to these various advantages of microfluidic devices made from PDMS, it has several
applications for neuroscience. It has been used

for neuron cell culture, neuron

manipulation, neural stem differentiation, neuropharmacology, neuro electrophysiology
and neuron biosensors

12

. In this regard, a multicompartment microfluidic device was

designed specifically for neuroscience research. This device is an improvement over the
Campenot chambers. The device has been extensively used for the study of Alzheimer’s
disease. These devices were used to isolate single axons and manipulate different regions
of the neurons 13.

10

Figure 1.4.c: Images of micro-channels in microfluidic devices cultured with neurons
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CHAPTER 2
Validation of click-labelled APP in primary cells
2.1 Experimental procedure
Primary cells- N2a, were used to test the click-labelled APP molecular tool. The cells were
transfected with APP-mClover DNA and APP-Amber-mClover DNA. Following transfections,
the cells were fixed and stained with antibodies. The cells were then imaged using confocal
microscopy and analyzed using Imaris. The analysis was based on colocalization of APP with
various subcellular. The total percent of colocalization of click-labelled and mClover tagged
APP was compared with wild-type APP-mClover.

2.2 Experimental protocols
2.2.1 Cell passaging and platingi. Media is aspirated from the flask and 3ml of PBS is added.
ii. PBS is aspirated and 2ml of 0.05% trypsin is added and incubated for 3 minutes.
iii. 8ml of media is added to stop the trypsin action and the cell count is taken.
iv. The cells are resuspended and 150uL of the cells are added to each well in the quadrant
dishes. ~17,000 N2a cells/well is added.

12

2.2.2 Transfectioni. Label two tubes per condition, one for DNA and one for lipofectamine
ii. Add opti-MEM to each tube
iii. Add lipofectamine to the lipo tube and incubate for 5 minutes at room temperature.
iv. Add DNA to the DNA tube.
v. Mix DNA with lipofectamine and incubate for 20 minutes at room temperature.
vi. Remove 50ul of media per well in quadrant dishes and add 50uL of DNA-lipofectamine
mixture.
vii. Incubate at 37oC for 6-8 hours. Remove transfection reagents.
viii.

Add media with unnatural amino acids (CPK+HEPES).

ix. Incubate at 37oC overnight.

2.2.3 Fixing and permeabilizing cellsi. Media is removed from the wells.
ii. Wash with 1xPBS.
iii. Add cold 4% PFA and incubate for 10 minutes. Wash with 1xPBS, thrice.
iv. Permeabilize cells with 0.3% triton X-100 for 10 minutes at room temperature.
v. Wash with 1x PBS.

2.2.4 Antibody stainingi. Add blocking agent to each well.
ii. Allow blocking for 30 minutes.
13

iii. For N2a cells plated on cover slips, transfer the coverslips to flat bottom box (place wet
tissues on either side to keep the box moist)
iv. Add primary antibody. Leave it for 30-45 minutes. Wash with 1x PBS, thrice.
v. Add secondary antibody. Leave for 30-45 minutes at room temperature.
vi. Wash with 1x PBS, thrice.
vii. For N2a cells plated on coverslips, add 10uL droplets of Gelvitol on a glass slide. Place
each cover slip on the droplets, so that the cells are in contact with Gelvitol (place inverted
with respect to plating). Allow the coverslip to get fixed on the slide. (About 1 hour).
Blocking agent for N2a- 1x PBS + 1% Saponin + 10% goat serum

2.2.5 Imaging –
The cells were imaged in Nikon A1R confocal microscopy. 100x resolution oil immersion were
used to visualize the cells. The wavelength of laser lights differed for different antibodies. The
antibodies of APP were colocalized with Golgi, lysosome, and endosomal subcellular markers. A
Z-stack image was captured.

2.2.5 Analysis –
The colocalization analysis was carried out using the Imaris software. The colocalization
analysis was carried out by picking the overlapping signal from APP and subcellular marker. The
percent APP was calculated by the APP intensity in a subcellular site divided by the total APP

14

intensity in cell. The percent APP was calculated for APP-Amber-mClover N2a and WT APPmClover N2a.

2.3 Results and discussion
2.3.1 Selection of subcellular antibodies:
The subcellular organelles involved in endocytic pathway of APP processing include early
endosomes, Golgi and trans-Golgi network and late endosome/ Lysosomes 3, 14. Various
antibodies were tested to get the best result for colocalization. EEA1 is an early endosomal
marker used for the current work. EEA1 is essential for early endosomal membrane fusion and
trafficking. Rab7 was used for late endosome and lysosomal marker. It is a Ras-related protein
and is important in late endocytic pathway. Golgin97 was used as the subcellular marker against
trans-Golgi network. Golgin97 is known to help maintain trans-Golgi integrity and function by
localization of TGN resident proteins.

Figure 2.3.1a: EEA1 antibody to identify early endosome

15

Figure 2.3.1b: Golgin97 antibody to identify trans-Golgi network

Figure 2.3.1c: Rab7 antibody to identify late endosome / lysosome
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2.3.2 Imaging:
The cells were imaged in oil immersion at 100X resolution. The Z-stack of the cells were
obtained. The colocalized images were captured.
APP-WT-mClover

EEA1

merge

Figure 2.3.2a: N2a cells stained with EEA1 and colocalization of mClover signal with EEA1

APP-WT-mClover

Rab7XP

merge

Figure 2.3.2a: N2a cells stained with Rab7 and colocalization of mClover signal with Rab7
Golgin97

merge

Figure 2.3.2a: N2a cells stained with Golgin97 and colocalization of mClover signal with Golgin97
17

2.3.3 Analysis:
The percent APP was calculated by the APP intensity in a subcellular site divided by the total
APP intensity in cell. The percent APP was calculated for APP-Amber-mClover N2a and WT

% of APPmClover
colocalized

APP-mClover N2a.

30

EEA1

20
10
0
APP WT mClover

APP Amber mClover

Figure 2.3.3a: Comparison of percent colocalization of APP with EEA1 in click-labelled and

% of APPmClover
colocalized

WT cells

55
45
35
25
15
5
-5

Rab7

APP WT mClover

APP Amber mClover

Figure 2.3.3b: Comparison of percent colocalization of APP with Rab7 in click-labelled and
WT cells
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% of APPmClover
colocalized

30
25
20
15
10
5
0

Golgin97

APP WT mClover APP Amber mClover

Figure 2.3.3c: Comparison of percent colocalization of APP with Golgin97 in click-labelled and
WT cells
The colocalization of click-labelled and WT APP-mClover was carried out and the percent APP
was found. We expect a co-occurrence with the sub-cellular markers and not a correlation. The
percent APP colocalized in both the cells are not very different indicating the click-labelling
doesn’t alter the trafficking. This shows that the tool is useful in visualizing APP trafficking.
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CHAPTER 3
Fabrication of microfluidic device to study APP trafficking in neurons
The neurons are a complex cell that have various organelles that are highly compartmentalized.
It consists of axons, dendrites and soma. The trafficking of proteins in these structures takes
place with the help of highly specialized trafficking organelles. Hence the trafficking of APP can
be complex in neurons and requires unique devices to study each part of a neuron. Microfluidics
can be exploited to study the trafficking of APP in neurons. These devices can fluidically isolate
soma and axons. This helps us in understanding the trafficking and processing of APP in axons.
This also allows us to manipulate the axons alone. Using this device, it is possible to click-label
axons alone or click label the synapses to visualize the APP trafficking.

3.1 Experiment procedure:
Microfluidic device was designed to isolate single axons in order to study APP trafficking. It
involves design, fabrication, testing and trouble-shooting of the device. The device is an open
channel type and was fabricated using soft lithography technique.
The device fluidically isolates the soma and the axon. The neurons are plated in the somal
chamber and the axons extend into the micro-channels and reach the axonal chamber. A volume
difference is maintained between the chambers which ensures that the flow is from soma to the
axon chamber. When the volume in both the chambers is kept equal, there is no flow between the
chambers creating a fluidic isolation.

20

3.2 Experimental protocols
3.2.1 Microfluidic device fabrication

1. Mask design- The mask was designed using AutoCAD 2017 software 15. The mask was
designed following the mask design rules from Stanford Microfluidic Foundry 16. The mask
design consists of two layers- micro-channels layer and chamber layer.

Figure 3.2.1a: First layer of the mask consisting of micro-channels and alignment marks
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Figure 3.2.1b: Second layer of the mask consisting of main channels

Figure 3.2.1c: Final mask design with both the layers

2. Device specifications- The micro-channels are 500um long, 5um wide, 10um deep and have
10um spacing between channels. The total channel count per device is approximately 300. The
current mask design consists of four pair of devices (eight devices in a mask). The space between

22

two adjacent devices is 2.5 mm. The main channels are 5 mm in length, 5mm in breadth and 100
um in depth 17.

Figure 3.2.2a: Microfluidic device dimensions- main channels and micro-channels

Table 3.1: Microfluidic device dimensions
Micro-channels

Main channels

Length

500 um

Width

5 um

Depth

10 um

Spacing

10 um

Length

5 mm

Width

5 mm

Depth

100 um

3. Mold fabrication- The mold was fabricated on a 3-inch silicon wafer. The mold was
fabricated in-house. The protocol for fabrication was followed from the paper by Park et.al. 2006.
Soft lithography technique was used for fabrication 15. The fabrication steps are as follows 18:
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i.

The 3-inch wafer is cleaned with acetone, isopropyl alcohol and sterile water. It is dried
with nitrogen.

ii.

The wafer is placed in the spin coater. Approximately 1ml of SU8-3010 photoresist is
added. It is spun at 3000 rpm for 32s at the rate of 300 rpm/s to obtain a height of 10um.

iii.

The wafer is soft baked at 95oC for 3 minutes.

iv.

Wafer is exposed through a high-resolution transparency mask containing the first layer
with micro-channels at 200 mJ/cm2.

v.

Post-exposure baked the wafer for 60 seconds at 65oC and 2 minutes at 95oC.

vi.

Developed with SU8 developer for 3 minutes.

vii.

A second layer of photoresist- SU8-2050 was spun at 1750 rpm for 32 seconds at the
rate of 300 rpm/s to get a height of 100um.

viii.

Soft baked at 65oC for 5 minutes and at 95oC for 20 minutes.

ix.

It was exposed through a high-resolution transparency mask containing the second
layer with man channels at 240 mJ/cm2.

x.

Post-exposure baked at 65oC for 2 minutes and at 95oC for 10 minutes.

xi.

Developed with SU8 developer for 10 minutes.

xii.

Wafer was cleaned with isopropyl alcohol and water, followed by drying with nitrogen
gas. The cleaned mold dimensions were measured using the profilometer.
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Figure 3.2.3: Microfluidic device mold fabricated on Si wafer using soft lithography

4. PDMS device fabrication- The PDMS device was made by replica molding technique. The
following steps were carried out:
i. PDMS and its activator are weighed out in a 10:1 ratio in a disposable container and mixed
thoroughly. Approximately 25g of PDMS was used for the devices to achieve a thickness
of about 5-7 mm.
ii. The PDMS is poured onto the mold. It is placed in vacuum desiccator for 30 minutes to
remove any air bubbles. Any remaining bubbles are removed by using pressurized air/
razor blade.
iii. The PDMS is cured in an oven at 70oC for more than 3 hours.
iv. The PDMS is removed from the mold and cut into individual devices.
v. 6 mm holes were punched into main channels.

5. Cleaning the devices- The devices are dynamically washed with 70% ethanol thrice,
followed by washing with sterile water. Any additional particles stuck on the PDMS surface was
removed using scotch tape.

6. Bonding- PDMS can be bond to glass slide reversibly or irreversibly 18. The devices were
bond reversibly by placing the device with the channels facing the glass and pressing it gently. The
device is bond to the glass by Van der Waal’s forces 11. It is bond irreversibly by UV exposure.
The PDMS device (the channels facing up) and glass slide are exposed to UV for 5 minutes and
bond together18.
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7. Coating- The bonded devices are coated with poly-D-lysine (PDL) and Laminin 19. 1ml of
0.1mg/ml of PDL is mixed with 35ug of Laminin. This mixture is added to the main channels and
incubated at 37oC overnight. The solution is removed and washed with sterile water.

3.2.2 Cell passaging and platingPrimary hippocampal cells are obtained from rat brain. [Courtesy of Dr. Steven Mennerick]
i. 1:1 dilution of neurons in media is made.
ii. 200uL of diluted cells is added to dishes coated with PDL+Laminin and incubated at
37oC overnight.
iii. In the microfluidic device, 120uL of media is added to one well (axonal chamber) and
150uL of diluted cells is added to the other well. This maintains a flow of media so that
neurons move close to the micro-channels.
iv. The devices are incubated at 37oC overnight.
3.2.3 Transfectioni. Label two tubes, one for DNA and one for lipofectamine
ii. Add Lipofectamine and MEM+ to lipofectamine tube and mix. Incubate for 5 minutes at
room temperature.
iii. Add DNA and MEM+ to DNA tube and mix.
iv. Mix DNA and lipofectamine tube and incubate for 20min at room temperature.
v. Warm remaining MEM+ in incubator
vi. Remove media from neurons with 10mL pipette and save for CPK addition
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vii. Add 100ul prewarmed MEM+ to each dish
viii.

Add 100ul transfection reagents dropwise to each dish. Incubate for 6 hours

ix. Aspirate transfection reagents + media
x. Add conditioned media + CPK + HEPES (Conditioned media:CPK=100:1; CPK:HEPES
= 5:1)
xi. Incubate at 37oC overnight.
MEM+ (1ml) = 1ml MEM+ 5uL APV + 2uL NBQX
3.2.4 Fixing and permeabilizing cellsi. Media is removed from the wells.
ii. Wash with 1xPBS.
iii. Add cold 4% PFA + 4% sucrose and incubate for 10 minutes. Wash with 1xPBS, thrice.
iv. Permeabilize cells with 0.3% triton X-100 for 10 minutes at room temperature.
v. Wash with 1x PBS.
3.2.5 Antibody stainingi. Add blocking agent to each well.
ii. Allow blocking for 30 minutes.
iii. Add primary antibody and incubate at 4oC overnight.
iv. Wash with 1x PBS, thrice.
v. Add secondary antibody. Leave for an hour at room temperature.
vi. Wash with 1x PBS, thrice.
vii. 1x PBS is added.
Blocking agent for neurons - 1x PBS + 0.3% triton X-100 + 3% Bovine serum albumin
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3.2.6 ImagingThe device with neurons were imaged using confocal microscopy. The Nikon A1Rsi, a scanning
confocal Microscopy at the Washington University Center for Cellular Imaging, was used for
imaging the samples. The images were viewed through 10x and 20x objective in oil immersion.

3.3 Results and discussion:
3.3.1 Devices used:
Four different devices were tested to see which device was compatible. We tested two
commercial devices and two lab made devices.
1. Devices from Xona Microfluidics - The microfluidic device is manufactured by Xona
Microfluidics 18. The device consists of four chamber wells, two main channels and microchannels. It is a closed type. The device can be segregated into axonal and somal chamber.
The dimensions of the device are as followsi.

Chamber wells are 5mm x 5mm, 8mm punched holes

ii.

Main channels are7 mm in length, 1.5 mm in width and 100uM in depth

iii.

Micro-channels are 500um in length, 5um in width, 3um in depth and 5um in
spacing.
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Figure 3.3.1a: Microfluidic device from Xona
2. Devices from Ananda devices- These microfluidic devices were manufactured from Ananda
devices 20. It is a closed type of device and consists of somal and axonal chambers. The
device consists of four chamber wells, two main channels and micro-channels. The
dimensions of the device are as followsi.

Chamber wells are 5mm x 5mm, 4mm punch holes

ii.

Main channels are 5mm in length, 1.5 mm in width and 100uM in depth

iii.

Micro-channels are 500um in length, 5um in width, 30um in depth and 30um in
spacing.

Figure 3.3.1b: Microfluidic device from Ananda
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3. Lab made devices- Two sets of devices were fabricated in the Institute of Material Science
and Engineering at Washington University in St Louis. The device is an open type device 17.
The device consists of two wells- somal and axonal wells, that are connected by microchannels. The dimensions of the device are as followsi.

Chamber wells are 5mm x 5mm, 6mm punch holes

ii.

Micro-channels are 500um in length, 5 um in width, 10um in spacing and 15/ 10 um
in depth.

Figure 3.3.1b: Lab made microfluidic devices

3.3.2 Device comparison:
1. Xona devices- The devices were easy to bond to the glass slides. The large punch holes
gave an easy access to angle the pipette. The reversibly bonded devices were found
to leak and the devices were UV bonded. The bonded devices were used to plate the
neurons. It was seen that neuron survival was low and no neurons were found near
the micro-channels. The devices could only be used a few times as it was difficult to
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remove the cell debris in the main channels. Due to these disadvantages the device
were not chosen to carry out any further studies.
2. Ananda devices- The devices easily bond to glass slides and were not UV bonded as
they were tightly sealed. The small punch holes made it difficult to angle the pipette
tip close to micro-channels. There was an improved survival of the neurons in the
somal chambers compared to that of Xona devices but very few neurons were found
in the main channels and none were close to the micro-channels to extend axons. The
devices were found to harden after a few uses and difficult to bond. Due to these
disadvantages the device was not chosen to carry out any further studies.
3. Lab-made devices (15um)- The lab made devices easily bond to the glass slides and the
large punch holes made for an easy access to angle the micropipette close to microchannels. There was a significant increase in the neurons that survived in the wells.
The neurons were growing close to the micro-channels and possible axon extension
into the channels were seen. But the micro-channel walls were not straight and was
difficult to segregate them. Due to these disadvantages the device was not chosen to
carry out any further studies.
4. Lab-made devices (10um)- The lab made devices easily bond to the glass slides and the
large punch holes made for an easy access to angle the micropipette close to microchannels. There was a significant increase in the neurons that survived in the wells.
The neurons were growing close to the micro-channels and axons were extending
into the channels. This device was selected.
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3.3.3 Trouble-shooting:
1. Micro-channels- The 15um devices had channels that were not straight and was difficult to
segregate. To overcome this problem, the height of the micro-channels was reduced to 10um.
This height reduced the strain on the walls and hence were straight.

Figure 3.3.3a: Micro-channels from 15um device with crooked walls

Figure 3.3.3b: Micro-channels from 10um device with straight walls
2. Cell debris- The micro-channels of 15um devices was blocked by cell debris. This prevented
the axons from extending into the micro-channels. Addition of AraC with the media reduced the
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cell debris. The angling of the micropipette slightly away from the micro-channels also reduces
the cell debris clogging the channels.

Figure 3.3.3c: Micro-channels blocked with cell debris

Figure 3.3.3d: Micro-channels with reduced cell debris
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3. Neuron survival- The devices coated with only PDL did not have any neurons surviving.
The devices were coated with PDL and laminin, incubated at 37oC for 2 hours. These had
very low survival rate. When the devices coated with PDL and laminin were incubated at
37oC overnight the neurons survived. The neurons survive in the devices for 14 days.

Figure 3.3.3e: Wells with low neuron count

Figure 3.3.3e: Wells with high neuron count
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4. Neurons growing underneath the channels- The axons were found to extend the neurons
underneath the channels in reversibly bonded devices. When the devices were UV bonded to
glass the axons were seen to grow only inside the channels.

Figure 3.3.3f: Axons growing underneath the channels

Figure 3.3.3g: Axons growing only in the channels
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3.3.4 Imaging:
The neurons plated in the devices were healthy and can survive up to 14 days in vitro.
The neurons that were 7 DIV were fixed, stained, and imaged. The neurons were stained
with SMI-312 marker known to stain axons. It is directed against highly phosphorylated
axonal epitopes of neurofilaments Heavy and Medium subunits. MAP2 marker was used
to stain the soma. A healthy number of neurons were seen in the somal chambers. The
axonal chamber was free of debris establishing fluidic separation from the somal
chamber. Axons were seen extending into the micro-channels.

SOMAL CHAMBER

MICROCHANNELS

AXONAL CHAMBER

Figure 3.3.4a: Parts of the microfluidic device
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MAP2

SMI 312`

Merged

Figure 3.3.4b: Neurons in the microfluidic device stained with neuronal markers

SMI 312`

MAP2

Figure 3.3.4b: Axons seen extending into the micro-channels and absence of dendrites
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